Association between blood lead and blood pressure: a population-based study in Brazilian adults

Ana Carolina Bertin de Almeida Lopes¹, Ellen Kovner Silbergeld², Ana Navas-Acien², Rachel Zamoiski³, Airton da Cunha Martins Jr.⁴, Alissana Ester Iakmiu Camargo⁵, Mariana Ragassi Urbano¹,⁶, Arthur Eumann Mesas¹,⁷ and Monica Maria Bastos Paoliello¹,⁸*

Abstract

**Background:** Environmental lead exposure among adults may increase blood pressure and elevate the risk of hypertension. The availability of data on blood lead levels (BLL) in adult Brazilian population is scarce and population-based studies are important for screening the population exposure and also to evaluate associations with adverse health effects. The goal of this study was to examine the association of BLL with blood pressure and hypertension in a population-based study in a city in Southern Brazil.

**Methods:** A total of 948 adults, aged 40 years or older, were randomly selected. Information on socioeconomic, dietary, lifestyle and occupational background was obtained by orally administered household interviews. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured according to the guidelines *VI Brazilian Guidelines on Hypertension*. BLL were measured by inductively coupled plasma mass spectrometry technique. Multiple linear and logistic regression models were performed to evaluate associations of BLL with SBP and DBP, and with the chance of hypertension and of elevated SBP and DBP.

**Results:** The geometric mean of BLL was 1.97 μg/dL (95%CI:1.90-2.04 μg/dL). After multivariable adjustment, participants in the quartile 4 of blood lead presented 0.06 mm/Hg (95%CI, 0.04-0.09) average difference in DBP comparing with those in quartile 1. Participants in the 90th percentile of blood lead distribution had 0.07 mmHg (95% CI, 0.03 to 0.11) higher DBP compared with those participants in the 10th percentile of blood lead. The adjusted OR for hypertension was 2.54 (95% CI, 1.17-5.53), comparing the highest to the lowest blood lead quartiles. Compared with participants in the 10th percentile of blood lead, participants in the 90th percentile presented higher OR for hypertension (OR: 2.77; 95% CI, 1.41 to 5.46).

**Conclusion:** At low concentrations, BLL were positively associated with DBP and with the odds for hypertension in adults aged 40 or older. It is important to enforce lead exposure monitoring and the enactment of regulatory laws to prevent lead contamination in urban settings.

**Keywords:** Blood lead, Blood pressure, Hypertension, Population-based

* Correspondence: monibas2@gmail.com

¹Graduate Program in Public Health, Center of Health Sciences, State University of Londrina - UEL, Londrina, Paraná, Brazil
²Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Chronic lead exposure and accumulation in the body can lead to progressive health effects. Among these effects, increased blood pressure, which is associated with the onset of cardiovascular diseases, has been linked to lead exposure. The hypertensive effects of lead have been widely reported in workers exposed to high levels of the metal and by experimental studies in which animals were exposed to long-term high doses of lead. Under occupational conditions, the development of hypertension has been implicated as a possible consequence of the nephropathy caused by lead exposure. Studies have concluded that lead exposure is a risk factor for raised blood pressure and hypertension even in the general population [1–4].

Publications of NHANES (National Health and Nutrition Examination Survey) data have reported a decline of environmental lead exposure in the United States and consequent lower blood lead concentrations in the American population. While early studies had noticed positive and significant associations between blood lead and blood pressure, more recent studies have questioned the consistency of this association in view of the lower blood lead concentrations observed in the last published data [5–10]. A meta-analysis of the epidemiological studies available from 1980 to 2001 reported that a 2-fold increase in blood lead concentration was associated with a 1.0 mm Hg increase in systolic blood pressure and a 0.6 mm Hg increase in diastolic blood pressure [11]. Recent data have suggested that the effect sizes in the associations of blood pressure and blood lead (mean of 1.51 μg/dL) are small and inconsistent [6], or that a modest association was found [12].

Hypertension is a major risk factor for cardiovascular disease, which remains the leading cause of death in Brazil, representing about 13% of disability adjusted life years (DALYs) [13, 14]. Globally, raised blood pressure is the leading noncommunicable diseases risk factor, to which 13% of deaths are attributed. The prevalence of raised blood pressure in adults aged 25 years or older was about 40% in 2008, and is generally more prevalent in men than in women (39% for men and 32% for women) [15]. In Brazil, the prevalence is similar to other countries, occurring in 35.8% of men and 30% of women with general estimate of over 30% in both sexes, and prevalence increases with age (≥60 years old) [16–18].

In view of the low blood lead concentrations found in our study (1.97 μg/dL) and the divergent results published on literature, we aimed to examine the relationship of blood lead with blood pressure and hypertension in a population-based sample of Brazilian adults living in southern Brazil. Besides, few studies have evaluated the scientific evidence on blood lead and adverse health effects on the Brazilian general population. Our study focused on adults aged 40 years or older who, as compared to younger persons have increased risk factors for cardiovascular diseases, and also were probably exposed to higher concentrations of lead before 1985, when the withdrawal of tetraethyl lead in automotive gasoline occurred in Brazil [19].

Methods
The study population included adults aged 40 years or older residents in an urban area in southern Brazil. In 2011, participants were randomly selected and took part in a household interview, anthropometric measurements and laboratory tests. Complete information of the study design and sampling has already been published [20, 21].

The accomplished study had a census based design, using data from the Population Count 2007, when the city of Cambé had a total of 92,888 people, of whom 30,710 (33.1%) were aged 40 or older (46% men and 54% women) [22]. All census tracts in the urban region were included in the study and the number of subjects to be interviewed in each tract was calculated proportionally to the amount of men and women aged 40 or over, and a quota of individuals, according to gender and age range, with five-year intervals was defined.

A total of 1180 (88.3%) of the selected persons completed the interview and 959 (81.3%) performed blood collection [20]. For the present analysis, we used data from 948 subjects who participated in the interviews, who had performed blood tests and had blood pressure measurements. Eleven participants missing information on blood pressure were excluded from this analysis.

The measurements were taken according to the VI Brazilian Guidelines on Hypertension, organized by the Brazilian Hypertension Society [23], by using the digital equipment Omron HEM 742. Measurements were obtained at both arms, and in case of difference, we used data from the arm with the highest value as a reference for subsequent measures. At least three measurements were performed with one minute interval between them, with the participant in a sitting position. The mean of the last two blood pressure measurements was considered the most accurate blood pressure. Participants were considered as hypertensive if any of the following criteria were present: a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg or higher, or self-reported use of antihypertensive medication. Systolic and diastolic blood pressures were also examined as separate dichotomous variables considering the same cutoff values.

Whole blood samples of approximately 5 ml were obtained by venipuncture after skin disinfection with alcohol 70%, collected in heparinized metal-free containers and kept under refrigeration until sent to the laboratory. Once in the laboratory, the samples were stored at
formation was obtained from the physical examination 
and calculated as weight in kilograms divided by the 
square of height in meters. Weight was measured with 
an electronic scale, with a precision of 0.1 kg and max-
imum capacity of 150 kg. The individuals were weighted 
and calculated as weight in kilograms divided by the 
square of height in meters. Weight was measured with 
an electronic scale, with a precision of 0.1 kg and max-
mum capacity of 150 kg. The individuals were weighted 
barefoot, standing upright at the center of the scale plat-
form and wearing light clothing. Height was measured 
with a portable stadiometer with a precision of 0.1 m 
and maximum length of two meters. The participants 
stood, barefoot, with their back turned to the vertical 
surface of the equipment and head positioned in the 
Frankfurt plane, with arms relaxed at the side of the 
body, with palms facing the thighs united heels, touching 
the vertical part of the stadiometer and medial edges 
spaced apart. The movable part of the stadiometer was 
elevated until touching the vertex, compressing the hair 
[21]. Current antihypertensive medication use was self-
reported and participants were considered as taking 
these medications according with the VI Brazilian 
Guidelines of Hypertension [23]. The antihypertensive 
medications were shown to the interviewer at the mo-
moment of the interview. However, some of these medica-
tions were prescribed for the treatment of congestive heart failure, and 
the medication verapamil retard (calcium channel 
blocker), used to treat cardiac arrhythmia, were not con-
sidered as current use of antihypertensive medication 
[25, 26]. In the case of diuretics use, a non-specific 
médication for the treatment of hypertension, the par-
ticipant was considered to have hypertension depending 
on the self-reported question. For this, the following 
question was asked to the respondent: “Which of the 
following diseases have you ever been told by a doctor 
or other health professional (doctor, nurse, pharmacist, 
etc.) do you have or had?” Total cholesterol, high-
density lipoprotein (HDL), triglycerides and glucose were 
performed using automated methodology to Dimension 
RXL biochemical system model. The low-density lipo-
protein (LDL) was calculated using the Friedewald equa-
tion [27].

For statistical analysis we used the software Stata [28] 
to perform descriptive and inferential statistical tests. 
Means, percentages and standard errors were estimated 
to describe the sample characteristics. Blood lead levels 
were left skewed and log transformed for analysis. Out-
come variables, systolic and diastolic blood pressures 
were, respectively, inverse and log transformed to follow 
normal distribution. Multiple linear regression models 
were performed to examine associations of blood lead 
with systolic and diastolic blood pressures comparing 
those participants in quartiles 2 to 4 of blood lead levels 
with those in quartile 1. Multiple logistic regression ana-
lysis was used to evaluate the risk of hypertension also 
by categorizing blood lead in quartiles. We also
performed Pearson correlation analysis to verify the correlations between systolic and diastolic blood pressure with blood lead levels.

Regression models were constructed based on a priori knowledge and biologic association with blood pressure (age, sex, antihypertensive medication use and blood lead log transformed). Other covariates were added to the model in two separated blocks: Model 1 – sex, age, race, income, education, antihypertensive medication and blood lead level; Model 2 – model 1 + total cholesterol, triglycerides, glycemia, smoking, alcohol consumption and body mass index. A third model was further adjusted for occupation status. These variables were included because they were significantly associated with blood pressure outcomes in at least one of the models performed before the inclusion of blood lead, considering a \( p < 0.20 \). Additionally, we performed regression analyses with only the subgroup that was not taking antihypertensive medication to elucidate if we would find significant changes in results. After running each model, the distribution of the residuals was tested for normality. Statistical tests with \( p \) value < 0.05 were considered statistically significant.

**Results**

The overall geometric mean of blood lead level was 1.97 \( \mu g/dL \) (95% CI, 1.89–2.04), and the means for the blood lead quartiles ranged from 0.96 \( \mu g/dL \) to 4.21 \( \mu g/dL \) in the lowest and higher quartile, respectively. Blood lead levels were higher in men, in older participants (50 to 59 years old), in non-white, in smokers and drinkers, and in subjects with normal BMI. Participants currently or former employed in lead industries had higher blood lead levels (2.65 \( \mu g/dL \); 95% CI, 2.31–3.05) than those not employed (Table 1).

Of the 948 participants in the sample, 519 (54.7%) were classified as hypertensive, of whom 398 were classified as hypertensive according to their systolic and/or diastolic blood pressures, and 121 if they self-reported use of antihypertensive medication. A total of 181 subjects had both systolic and diastolic hypertension, 164 had only systolic hypertension, 53 had diastolic hypertension. Among the 220 untreated subjects, 73 had systolic hypertension only, 39 had diastolic hypertension, and 108 had both systolic and diastolic hypertension. Of those who reported being treated for hypertension (\( n = 299 \)), 91 had only systolic hypertension, 14 had diastolic hypertension, and 73 had both systolic and diastolic hypertension. Participants with hypertension (systolic blood pressure \( \geq 140 \) mm Hg, diastolic blood pressure \( \geq 90 \) mm Hg, or self-reported use of antihypertensive medication) had higher blood lead levels (2.04 \( \mu g/dL \); 95% CI, 1.94–2.15) than those not hypertensive (1.87 \( \mu g/dL \); 95% CI, 1.77–1.98) (Tables 1 and 2). The results of the Pearson correlation analysis for systolic blood pressure and blood lead levels was \( r = 0.088, p < 0.005 \), and for diastolic blood pressure the coefficient was \( r = 0.112, p < 0.005 \).

In unadjusted analysis, participants with elevated systolic and diastolic blood pressure presented higher blood lead concentration (2.16 \( \mu g/dL \); 95% CI, 2.02–2.31) and (2.31 \( \mu g/dL \); 95% CI, 2.13–2.51), compared with those with normal systolic and diastolic blood pressure (1.86 \( \mu g/dL \); 95% CI, 1.78–1.95) and (1.86 \( \mu g/dL \); 95% CI, 1.79–1.94), respectively. Hypertensive individuals had increased concentrations of total cholesterol, triglycerides and glycemia than those not hypertensive. Controversially, we observed that participants with higher levels of HDL had higher blood lead concentrations than those with decreased HDL (Tables 1 and 2).

In multivariate analysis, there was a weak association of blood lead with both systolic and diastolic blood pressure. After multivariable adjustment, participants in the quartile 4 of blood lead presented 0.06 mm Hg (95% CI, 0.04–0.09) average difference in diastolic blood pressure comparing with those in quartile 1. For systolic blood pressure, the average difference was almost insignificant (Table 3). Participants in the 90th percentile of blood lead distribution had 0.07 mmHg (95% CI, 0.03 to 0.11) higher diastolic blood pressure compared with those participants in the 10th percentile of blood lead. The geometric mean of blood lead level of participants in the 10th percentile and in the 90th percentile was 0.74 \( \mu g/dL \) (95% CI, 0.71–0.77) and 6.03 \( \mu g/dL \) (95% CI, 5.52–6.58), respectively.

The adjusted OR for hypertension comparing the highest to the lowest blood lead quartiles was 2.54 (95% CI, 1.17–5.53). Compared with participants in the 10th percentile of blood lead, participants in the 90th percentile presented higher OR for hypertension (OR: 2.77; 95% CI, 1.41 to 5.46) (Table 4).

When we further adjusted for occupational status, the results did not significantly change and the overall significance was maintained.

The results of the multivariate analysis when considering only the subjects not taking antihypertensive medication (\( n = 649 \)) were similar to those results of the sample including the whole population. Only a minor centesimal difference was observed for the OR and 95% CI as shown in Tables 3 and 4.

**Discussion**

In this study we found a significant association between small increases in blood lead levels and elevations in systolic and diastolic blood pressures. The association of blood lead was +0.06 mm Hg (\( p < 0.001 \)) for diastolic blood pressure, while the association for systolic blood pressure was statistically significant (\( p < 0.05 \), with no
| Characteristic          | n (%) | Percentile 50th (median) | Interquartile range | Min – max values | Geometric means (95% CI) | p-Value |
|-------------------------|-------|--------------------------|---------------------|------------------|--------------------------|---------|
| Overall                 | 948 (100) | 1.94                     | 1.44                | 0.46 – 45.62     | 1.97 (1.90, 2.04)         |         |
| Sex                     |       |                          |                     |                  |                          |         |
| Male                    | 421 (44.4) | 2.46                     | 1.72                | 0.65 – 45.62     | 2.59 (2.46, 2.73)         | <0.001  |
| Female                  | 527 (55.6) | 1.59                     | 0.99                | 0.46 – 27.91     | 1.58 (1.51, 1.65)         |         |
| Age (years)             |       |                          |                     |                  |                          |         |
| 40 – 49                 | 386 (40.7) | 1.83                     | 1.46                | 0.48 – 27.91     | 1.84 (1.73, 1.96)         | 0.001   |
| 50 – 59                 | 294 (31.0) | 2.09                     | 1.42                | 0.54 – 21.83     | 2.13 (2.00, 2.28)         |         |
| ≥ 60                    | 268 (28.3) | 1.94                     | 1.36                | 0.46 – 45.62     | 1.98 (1.84, 2.12)         |         |
| Race                    |       |                          |                     |                  |                          |         |
| White                   | 562 (59.3) | 1.87                     | 1.42                | 0.46 – 45.62     | 1.88 (1.79, 1.97)         | 0.084   |
| Non white               | 386 (40.7) | 2.03                     | 1.48                | 0.49 – 24.49     | 2.09 (1.97, 2.23)         |         |
| Education (years)       |       |                          |                     |                  |                          |         |
| 0 – 3                   | 229 (24.2) | 1.99                     | 1.28                | 0.46 – 10.78     | 1.94 (1.81, 2.08)         | 0.055   |
| 4 – 7                   | 357 (37.7) | 1.94                     | 1.51                | 0.51 – 45.62     | 2.00 (1.88, 2.14)         |         |
| 8 – 11                  | 265 (28.1) | 1.99                     | 1.64                | 0.49 – 27.91     | 2.03 (1.88, 2.20)         |         |
| 12 or more              | 97 (10.0)  | 1.74                     | 0.94                | 0.68 – 8.79      | 1.72 (1.56, 1.90)         |         |
| Income class<sup>b</sup> |      |                          |                     |                  |                          |         |
| A and B                 | 348 (36.8) | 1.95                     | 1.44                | 0.48 – 45.62     | 1.97 (1.85, 2.11)         | 0.259   |
| C                       | 514 (54.3) | 1.97                     | 1.49                | 0.46 – 13.03     | 1.98 (1.88, 2.08)         |         |
| D and E                 | 85 (8.9)  | 1.74                     | 1.20                | 0.51 – 24.49     | 1.85 (1.61, 2.11)         |         |
| Occupation              |       |                          |                     |                  |                          |         |
| Exposed to lead         | 114 (12.0) | 2.48                     | 2.11                | 0.7 – 45.62      | 2.65 (2.31, 3.05)         | <0.001  |
| Not exposed to lead     | 834 (88.0) | 1.89                     | 1.35                | 0.46 – 27.91     | 1.89 (1.82, 1.96)         |         |
| Smoking                 |       |                          |                     |                  |                          |         |
| Never                   | 498 (52.5) | 1.71                     | 1.10                | 0.46 – 45.62     | 1.68 (1.59, 1.76)         | <0.001  |
| Former                  | 268 (28.3) | 2.05                     | 1.57                | 0.56 – 8.53      | 2.11 (1.98, 2.25)         |         |
| Current                 | 182 (19.2) | 2.64                     | 2.18                | 0.87 – 27.91     | 2.73 (2.50, 2.98)         |         |
| Alcohol Consumption     |       |                          |                     |                  |                          |         |
| Do not drink            | 584 (61.6) | 1.74                     | 1.19                | 0.46 – 27.91     | 1.74 (1.67, 1.83)         | <0.001  |
| Drink                   | 364 (38.4) | 2.26                     | 1.72                | 0.56 – 45.62     | 2.38 (2.24, 2.53)         |         |
| Systolic blood pressure |       |                          |                     |                  |                          |         |
| < 140 mm Hg             | 603 (63.6) | 1.88                     | 1.39                | 0.48 – 27.91     | 1.86 (1.78, 1.95)         | <0.001  |
| ≥ 140 mm Hg             | 345 (36.4) | 2.07                     | 1.58                | 0.46 – 45.62     | 2.16 (2.02, 2.31)         |         |
| Diastolic blood pressure|       |                          |                     |                  |                          |         |
| < 90 mm Hg              | 714 (75.3) | 1.86                     | 1.35                | 0.46 – 45.62     | 1.86 (1.79, 1.94)         | <0.001  |
| ≥ 90 mm Hg              | 234 (24.7) | 2.19                     | 1.73                | 0.50 – 24.49     | 2.31 (2.13, 2.51)         |         |
| Hypertension<sup>c</sup> |      |                          |                     |                  |                          |         |
| No                      | 429 (45.3) | 1.88                     | 1.46                | 0.49 – 27.91     | 1.88 (1.77, 1.98)         | 0.099   |
| Yes                     | 519 (54.7) | 2.00                     | 1.47                | 0.46 – 45.62     | 2.04 (1.94, 2.15)         |         |
| Glycemia (mg/dL)        |       |                          |                     |                  |                          |         |
| < 100                   | 499 (52.6) | 1.85                     | 1.42                | 0.49 – 27.91     | 1.91 (1.81, 2.01)         | 0.278   |
| ≥ 100                   | 449 (47.4) | 2.00                     | 1.44                | 0.46 – 45.62     | 2.03 (1.92, 2.15)         |         |
difference observed in the 95% CI, showing a modest increase. However, the OR for hypertension was higher in participants in the quartile 4 of blood lead compared with those in the quartile 1 (OR = 2.54; 95% CI, 1.17–5.53). The geometric mean blood lead concentration of 1.97 μg/dl (95% CI, 1.89–2.04) found in the present study was higher than the concentration of 1.64 μg/dl reported by Bushnik et al. [12], in a survey at national level with the Canadian population aged 40 to 79 years old. These authors reported a significant association between systolic and diastolic blood pressure and lead concentrations for subjects aged 40 to 54 years old and for men, but not with the odds for hypertension [12].

Prospective studies have suggested that there is sufficient evidence to infer a causal relationship of lead exposure with hypertension, besides the modest strength

| Characteristics | Hypertension (n = 519) | No hypertension (n = 429) | All (n = 948) | P value |
|-----------------|------------------------|--------------------------|--------------|---------|
| Age (years)     | 57.6 (0.46)            | 50.9 (0.44)              | 54.5 (0.34)  | <0.001  |
| Sex (% male)    | 42 (0.02)              | 47 (0.02)                | 44.5 (0.16)  | 0.114   |
| Race (% white)  | 58 (0.02)              | 61 (0.02)                | 59 (0.01)    | 0.375   |
| Education (years of study) | 5.62 (0.19) | 7.24 (0.21) | 6.35 (0.14) | <0.001  |
| Income class (% middle income class) | 59 (0.02) | 48 (0.02) | 54 (0.02) | 0.011   |
| Smoking         |                        |                          |              |         |
| Former smoker (%) | 32 (0.02)              | 23 (0.02)                | 28.3 (0.01)  | 0.001   |
| Current smoker (%) | 16 (0.16)              | 23 (0.02)                | 19 (0.01)    |         |
| Alcohol intake (% drinker) | 42 (0.02) | 36 (0.02) | 38.4 (0.01) | 0.055   |
| Total cholesterol (mg/dL) | 206.8 (1.83) | 200.5 (1.80) | 203.9 (1.29) | 0.020   |
| Triglycerides (mg/dL) | 169.4 (7.65) | 129.2 (5.04) | 151.2 (4.81) | <0.001  |
| Glycemia (mg/dL) | 110.1 (1.52)          | 98.9 (0.89)             | 105.0 (0.94) | <0.001  |
| BMI (Kg/m²)     | 28.9 (0.23)            | 26.9 (0.27)             | 27.9 (0.18)  | <0.001  |
| Blood lead (μg/dL) | 2.04 (1.94-2.15)       | 1.87 (1.77-1.98)        | 1.97 (1.89-2.04) | 0.029   |
| Occupation (% lead exposed) | 11 (0.01) | 13 (0.02) | 12.0 (0.01) | 0.278   |

Hypertension defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or antihypertensive medication use. Chi-square, Wilcoxon or Kruskal-Wallis test. According to Associação Brasileira de Empresas de Pesquisa (ABEP, 2012); from 0 (lower income level) to 45 (higher income level). Geometric mean (95% CI); other results in the table are arithmetic means or percentages (SE).
observed in these associations [3, 29–31]. Bone lead is considered a long-term biomarker for lead exposure, representing a cumulative dose in the body, which has been considered a better assessment of lead in epidemiological studies evaluating associations of cumulative exposures with chronic disease. Blood lead represents a short-term biomarker, reflecting recent exposure to the metal, but also provide variability of lead released from the bones [32]. The mobilization of lead from bone is increased during some periods of life, such as aging, pregnancy and after the menopause in women [10, 32, 33]. Studies that measured both bone and lead reported that bone lead (patella and tibia bones), was positively associated with hypertension, while blood lead was mostly associated with raised blood pressure [34, 35]. So the associations found between bone lead and current blood pressure indicate that past exposure as well as current exposure to lead are important biomarkers to evaluate blood pressure outcomes.

Studies with general population also found positive associations between blood lead concentrations and elevation on both systolic and diastolic blood pressure [6, 12, 34, 36, 37]. We identified a most significant association of blood lead with diastolic blood pressure (0.06 mmHg; 95% CI, 0.04–0.09), while other studies reported most significant associations of blood lead with systolic blood pressure comparing with diastolic blood pressure [6, 9, 10, 31, 34–38]. This variability is difficult to be enlightened and may not be restricted to intrinsic factors of blood pressure, but also depends on the measurement technique used, the measurer’s ability, and other conditions under which the measure will be held [2].

Most recently, Hara et al. [6] reported that blood lead doubling was associated with higher systolic (+0.76 mm Hg; 95% CI, 0.38–1.13) and diastolic blood pressure (+0.43 mm Hg; 95% CI, 0.18–0.68), but not with the odds of prevalent hypertension in analyzing data from NHANES 2003–2010. Besides that, the study reported the results of stratified analysis of blood lead and blood pressure by sex and ethnicity, revealing distinct results regarding each population stratum [6]. Before that, Scinicariello et al. [39] published data from NHANES 1999–2006 and reported that blood lead was significantly associated with higher diastolic blood pressure among white men and women and in black men, while elevated systolic blood pressure was associated with blood lead only in blacks, but not in whites or in Mexican-American participants. Compared with American population, Brazilian adults may be exposed to distinct sources of lead, and the influence of covariates may differ [20]. Besides, although the present study is based on a representative sample of adults, the number of participants did not allow us to perform a fully stratified analysis.

Unlike what has been observed on the hypertensive effects of lead in studies involving workers exposed to high levels of lead, environmental exposure is often asymptomatic and as other toxic effects of lead, the magnitude of raised blood pressure depends on the magnitude of the exposure [2, 3, 5, 11, 40, 41]. Another
perspective on the health effects of lead-associated increases in blood pressure is to consider the effect of a unit increase in median BLL on the overall distribution of blood pressure values in a population and the effect on number of persons with blood pressure elevations associated with stroke and other endpoints. This was calculated by Schwartz [42], who reported that a 1 μg/dL increase in mean population blood lead in US white males aged 40–59, distributed over the range of blood pressure values in this population, would increase the numbers of persons at risk for myocardial infarction by 3200 per year, of strokes by 1300 per year, as well as an overall increase in clinical hypertension of 635,000 more cases. Pirkle et al. [43], using the opposite approach, based on a longitudinal analysis of NHANES II data, from 1976 to 1980, in which blood lead levels in white males aged 40 to 59 years decreased by 37%, found that this decrease resulted in 4.7% and 6.7% decrease in fatal and nonfatal myocardial infarctions and strokes, respectively [43].

The inclusion of confounding factors in regression models has been considered very important to control for residuals in such analysis, especially when examining small effects as the influence of lead in blood pressure [10]. The inclusion of inappropriate covariates in regression models can attenuate associations between lead levels and the studied outcomes. Still, the absence of certain variables in the analysis may overestimate the strength of the association [9, 34, 40]. In this study, we included in the analysis risk factors for cardiovascular disease such as smoking, alcohol consumption, sex, age, socioeconomic and demographic variables and BMI to account for covariates that are known to be associated with blood pressure outcomes. Even so, some unmeasured variables not included in the analysis may influence the association of lead and blood pressure as, for example, pre-existing diseases, genetic aspects and renal function [40].

Although not completely elucidated, some mechanisms of lead-related hypertension have been reported, such as: impaired renal function, reduction of nitric oxide (NO) bioavailability, increased oxidative stress, increased activity of the renin angiotensin system and down-regulation of soluble guanylate cyclase. As a consequence of such mechanisms, lead exposure leads to increased vascular tone and induce alterations of the adrenergic system leading to endothelial dysfunction [41]. Barbosa Jr et al. [57] reported that lead exposure exerted a significant inhibitory effect on NO production, as shown by analyses of nitrite concentrations in adults living in the Southeast region of Brazil, suggesting that this biological mechanism is possibly related to the increased cardiovascular risk associated with lead exposure.

Some positive points to be highlighted in our study are the census based and the spatial analysis used to enroll participants. Besides that, the study included the measurement of multiple anthropometric and socioeconomic characteristics and the standardization of blood pressure measurements (≥3 readings) based on Brazilian Guidelines, taken by trained researchers. However, some limitations of this study are the cross-sectional design that does not allow causal inferences about the association of blood lead and blood pressure; and the fact that we may not have measured all the potential confounders of the relationship between hypertension and lead exposure.

Finally, we found that participants in the highest quartile of blood lead had an OR for hypertension of 2.54 (95% CI, 1.17–5.53), compared with those in the lowest quartile, as well as participants in the 90th percentile of blood lead presented higher OR for hypertension than those in 10th percentile. Differences observed among the results of other studies may be related to methodological issues, as bone lead measurement as a marker of lead exposure compared with blood lead and to stratified statistical analysis, which have shown that distinct risk
factors for lead exposure exist among these populations. Although education and income have been considered significant predictors of blood lead levels in Americans, the historically difference observed among income level has been decreasing. Furthermore, some Pb-related outcomes, including blood pressure outcomes, may vary by race/ethnicity, providing some evidence that some groups may be at higher risk of developing some diseases [7, 44, 58]. In Brazil these characteristics may have specific associations with both blood lead levels and hypertension, indicating that more studies with Brazilian adults are necessary to evaluate Pb-related health outcomes, as well as to provide an evaluation of blood lead levels in the general population.

Conclusions
We found a positive association between blood lead and diastolic blood pressure, and a significant association of blood lead and hypertension in Brazilians aged 40 years or older, living in southern Brazil. Our results add knowledge about the health risks associated with current environmental exposures to lead in Brazil, and encourage efforts to prevent lead exposure in the general population.

Abbreviations
AEBP: Associação Brasileira de Empresas de Pesquisa; AP-1: Activator protein-1; BLM: Body mass index; CCEB: Economic Classification Criterion Brazil; CI: Confidence interval; CNAE: National Classification of Economic Activities; DALYs: Disability adjusted life years; DBP: Diastolic blood pressure; HDL: High-density lipoprotein; ICP-MS: Inductively coupled plasma mass spectrometry; LDL: Low-density lipoprotein; NF-κB: Nuclear factor-κB; NHANES: National Health and Nutrition Examination Survey; NIST: National Institute of Standards and Technology; NO: Nitric oxide; OR: Odds ratio; Pb: Lead; SBP: Systolic blood pressure

Acknowledgements
“Not applicable” in this section.

Funding
This work was supported by the Coordination for the Improvement of Higher Level or Education Personnel (CAPES), through the Ministry of Health, Brazil.

Availability of data and supporting materials section
The study data are located in a secure server at the State University of Londrina, Brazil. All data are identified. The data are available upon request following the appropriate procedures of the VIGICARDIO Steering Committee (VIGICARDIO project: Cardiovascular diseases in Paraná State: Mortality, risk profile, drug therapy and complications). In summary, to get access to the data, external investigators need to submit a proposal indicating the objectives and analysis plan for accessing and analyzing the data. The study will be reviewed by the Steering Committee before approval. I am available for further information, Monica Maria Bastos Paoliello.

Author’s contributions
ACBAL, MMBP, EKS, ANA, RZ and AEM made contributions to conception, design, epidemiological analysis and data interpretation, drafting, and linking the exposure and health data. MRU made contributions to statistical analysis, and ADC and ACMJ contributed to conception, design, and biological material analysis. All authors have made contributions and approved the final manuscript.

Competing interests
We declare that we have no actual or potential competing financial interests.

Consent for publication
“Not applicable” in this section.

Ethics approval and consent to participate
This cross-sectional study is part of a research project entitled “Cardiovascular diseases in Paraná State: Mortality, risk profile, drug therapy and complications” – VIGICARDIO Study [21]. In compliance to the provisions in Resolution 196/96 from the National Health Council, Brazil, this research was approved by the Ethics Committee of the State University of Londrina, Paraná State, Brazil, with the issuance of opinion n. 236/10. Participants were asked to sign a consent form after the presentation of the research objectives. Each volunteer consented to the publication of data. For each interview, two copies of the consent form were issued, one being given to the volunteer.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Graduate Program in Public Health, Center of Health Sciences, State University of Londrina - UEL, Londrina, Paraná, Brazil. 2Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3Radiation Epidemiology Branch of the Division of Cancer Epidemiology and Genetics National Cancer Institute, National Institutes of Health, Washington D.C., USA. 4Graduate Program in Toxicology, Faculty of Pharmaceutical Sciences of University of São Paulo – USP, Ribeirão Preto, São Paulo, Brazil. 5Graduate Program in Health Sciences, Center of Health Sciences, State University of Londrina - UEL, Londrina, Paraná, Brazil. 6Department of Statistics, State University of Londrina - UEL, Londrina, Paraná, Brazil. 7Department of Public Health, State University of Londrina – UEL, Londrina, Paraná, Brazil. 8Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Received: 9 July 2016 Accepted: 3 March 2017
Published online: 14 March 2017

References
1. Toxicological profile for lead. [http://www.atdr.cdc.gov/toxprofiles/tp13.pdf]. Accessed 12 July 2016.
2. U.S. Environmental Protection Agency. Air Quality Criteria for Lead. [https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=158823]. Accessed 12 July 2016.
3. Navas-Acien A, Guillar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease—a systematic review. Environ Health Perspect. 2007;115(3):472–82.
4. Schwartz BS, Hu H. Adult lead exposure: time for change. Environ Health Perspect. 2007;115(3):451–4.
5. Den Hond E, Nawrot T, Staessen JA. The relationship between blood pressure and blood lead in NHANES III. National Health and Nutritional Examination Survey. J Hum Hypertens. 2002;16(8):563–8.
6. Hara A, Thijs L, Asayama K, Gu YM, Jacobs L, Zhang ZY, Liu YP, Nawrot TS, Staessen JA. Blood pressure in relation to environmental lead exposure in the national health and nutrition examination survey 2003 to 2010. Hypertension. 2015;65(1):62–9.
7. Muntner P, Menke A, DeSalvo KB, Rabito FA, Batuman V. Continued decline in blood lead levels among adults in the United States: the National Health and Nutrition Examination Surveys. Arch Intern Med. 2005;165(18):2155–61.
8. Harlan WR. The relationship of blood lead levels to blood pressure in the U. S. population. Environ Health Perspect. 1988;78:9–13.
9. Schwartz J. The relationship between blood lead and blood pressure in the NHANES II Survey. Environmental Health Perspectives. 1988;78(15–22).
10. Nach D, Magder L, Lustberg M, Sherwin RW, Rubin RJ, Kaufmann RB, Silbergeld EK. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. Jama. 2003;289(12):1523–32.
11. Nawrot TS, Thijs L, Den Hond EM, Roels HA, Staessen JA. An epidemiological re-appraisal of the association between blood pressure and blood lead: a meta-analysis. J Hum Hypertens. 2002;16(2):123–31.
12. Bushnik T, Levallois P, D’Amour M, Anderson TJ, McAlister FA. Association between blood lead and blood pressure: Results from the Canadian Health Measures Survey (2007 to 2011). Health Rep. 2014;25(7):12–22.
13. Schmidt MI, Duncan BB, Azevedo Silva GA, Menezes AM, Monteiro CA, Barreto SM, Chor D, Menezes PR. Chronic non-communicable diseases in Brazil: burden and current challenges. Lancet. 2011;377(9761):1949–51.

14. Schramm JMA, Oliveira Afrid, Leite IdaC, Valente JG, Gadelha AMJ, Portela MC, Campos MR. Transição epidemiológica e o estudo de carga de doença no Brasil. Ciência & Saúde Coletiva. 2004;9(7):997–1008.

15. WHO. Global status report on noncommunicable diseases 2010. Burden, mortality, morbidity and risk factors. 2010:p–11.

16. Ibrahim MM, Damasceno A. Hypertension in developing countries. Lancet. 2012;380(9841):611–9.

17. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009;27(5):963–75.

18. Picon RV, Fuchs FD, Moreira LB, Fuchs SC. Prevalence of hypertension among elderly persons in urban Brazil: a systematic review with meta-analysis. Am J Hypertens. 2013;26(4):541–8.

19. Paolillo MM, De Capitani EM. Environmental contamination and human exposure to lead in Brazil. Rev Environ Contam Toxicol. 2005;184:59–96.

20. Almeida Lopes ACBD, Navas-Acien A, Zamoiski R, Silbergeld EK. Cardiovascular disease and lead exposure in adult population in southern Brazil. J Toxicol Environ Health A. 2015;78(2):92–108.

21. Souza RKT, Bortoletto MSS, Loch MR, González AD, Matsuo T, Cabrera MAS, Remondi FA, Yonamine CY. Prevalence of cardiovascular disease: results from the Third National Health and Nutrition Examination Survey for England 1995. J Hum Hypertens. 1999;13(2):123–30.

22. Instituto Brasileiro de Empresas de Pesquisa. Contagem da população. [http://www.ibge.gov.br/home/estatistica/populacao/contagem2007/default.shtml]. Accessed 28 July 2015.

23. SBH: Sociedade Brasileira de Hipertensão. VI Diretrizes Brasileiras de Hipertensão. Revista Hipertensão. 2010;1(3).

24. Associação Brasileira de Empresas de Pesquisa. Critério de Classificação Econômica Brasil. http://www.abepe.org/criterio-brasil. Accessed 12 July 2016.

25. Bocchi EA, Marcondes-Braga FG, Bacal F, Ferraz AS, Albuquerque D, Rodrigues D, Sociedade Brasileira de Cardiologia. Atualização da Diretrizes Brasileira de Insuficiência Cardíaca Crônica. Arq Bras Cardiol. 2012;98(1supl):1–33.

26. Lorga A, Filho AL, D’Avila A, Jr AR, Paola AA, Pedrosa A, Costa AB, Peres A, Grup C, Cirenza C, et al. Diretrizes para Avaliação e Tratamento de Insuficiência Cardíaca. Arq Bras Cardiol. 2012;98(1supl):1–33.

27. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):1999–502.

28. STATACORP. Stata Statistical Software: Release 14. StataCorp LP. 2015.

29. Glenn BS, Steward WF, Links JM, Todd AC, Schwartz BS. The longitudinal association of lead with blood pressure. Epidemiology. 2003;14(1):30–6.

30. Moller L, Kristensen TS. Blood lead as a cardiovascular risk factor. Am J Epidemiol. 1992;136(9):1091–100.

31. Weiss ST, Munoz A, Stein A, Sparrow D, Speizer FE. The relationship of blood lead levels with blood pressure and its cardiovascular risk implications. Am J Epidemiol. 1985;121(2):246–58.

32. Schwartz J. Lead, blood pressure and cardiovascular disease in men. Arch Environ Health. 1995;50(1):131–7.

33. Pirkle JL, Schwartz J, Landis JR, Harlan WR. The relationship between blood levels and blood pressure and its cardiovascular risk implications. Arch Intern Med. 1995;165(17):2067–72.

34. U.S. (Environmental Protection Agency). Integrated Science Assessment for Lead. [http://cfpub.epa.gov/ncea/cfm/recorddisplay.cfm?md5id=255721-Download]. Accessed 14 Oct 2015.

35. Wang L, Wang H, Mu C, Cao J, Chen D, Liu Z. Oxidative stress and apoptotic changes in primary cultures of rat proximal tubular cells exposed to lead. Arch Toxicol. 2009;83(5):417–27.

36. Vaziri ND, Lin CY, Farmand F, Sindhu RK. Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced hypertension. Kidney Int. 2003;63(1):186–94.

37. Farmand F, Ehdai A, Roberts CK, Sindhu RK. Lead-induced dysregulation of superoxide dismutases, catalase, glutathione peroxidase, and guanylate cyclase. Environ Res. 2005;98(1):33–9.

38. Pande M, Flora SJ. Lead induced oxidative damage and its response to combined administration of alpha-lipoic acid and succinates in rats. Toxicology. 2002;177(2–3):187–96.

39. Martinez-Haro M, Green AJ, Mateo R. Effects of lead exposure on oxidative stress biomarkers and plasma biochemistry in waterbirds in the field. Environ Res. 2011;111(4):330–8.

40. Vaziri ND, Khan M. Interplay of reactive oxygen species and nitric oxide in the pathogenesis of experimental lead-induced hypertension. Clin Exp Pharmacol Physiol. 2007;34(9):920–5.

41. Vaziri ND. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2008;295(2):H454–65.

42. Cai H, Harrison DG. Endothelial Dysfunction in Cardiovascular Diseases: The Role of Oxidant Stress. Circ Res. 2000;86(10):840.

43. Vaziri ND, Rodriguez-Turbe B. Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006;2(10):582–93.

44. Lokkenen J, Naarala J, Vahakangas KH, Savolainen KM. Glutamate increases toxicity of inorganic lead in GT-7 neurons: partial protection induced by flumazenil. Arch Toxicol. 2003;77(12):663–71.

45. Ding Y, Gonick HC, Vaziri ND. Lead promotes hydralazine radical generation and lipid peroxidation in cultured aortic endothelial cells. Am J Hypertens. 2001;14(3):552–5.

46. Korashy HM, El-Kadi AOS. The role of redox-sensitive transcription factors NF-kB and AP-1 in the modulation of the Cyp1a1 gene by mercury, lead, and copper. Free Radic Biol Med. 2008;44(5):795–806.

47. Barbosa Jr F, Sertorio JT, Gerlach RF, Tanus-Santos JE. Clinical evidence for lead-induced inhibition of nitric oxide formation. Arch Toxicol. 2006;80(12):811–6.

48. Scinicariello F, Yesuprya A, Chang MH, Fowler BA. Modification by ALAD of the association between blood lead and blood pressure in the U.S. population: results from the Third National Health and Nutrition Examination Survey. Environ Health Perspect. 2010;118(2):259–64.